{"entity":{"id":"delivery-target-versus-therapeutic-target","kind":"term","name":"Delivery targets and therapeutic targets","aka":["delivery targeting versus cancer targeting","delivery receptor versus effector target"],"tldr":"The molecule used to deliver an intervention to a cell can differ from the target of the treatment that cell produces. Both targeting steps need to be named.","summary":"A primary mouse cardiac-fibrosis study used CD5-targeted lipid nanoparticles to deliver RNA encoding a receptor directed against fibroblast activation protein. CD5 specified a delivery interaction; the encoded receptor had a different recognition target. This is a non-oncology preclinical illustration of the distinction, not cancer-treatment evidence. Delivery, expression, effector recognition and clinical benefit should retain their separate experiments and biological settings.\n\nTargeted-LNP studies show three separate questions. Which cells receive usable cargo: in the CD5 study mRNA reached most cultured mouse T cells (83 per cent expressed the receptor, against 7 per cent with isotype-control particles) and receptor expression appeared across the main T-cell subsets in injured mice, while liver expression occurred with both CD5 and control particles; recombination in a Cre reporter reached 81.1 per cent of CD4-positive and 75.6 per cent of CD8-positive splenocytes but also 15.0 per cent of CD3-negative cells, and the statement that 87 per cent of receptor-positive cells were CD4-positive is a share of expressing cells, not the share of CD4 T cells that expressed the receptor, so each percentage needs its denominator. What the receptor recognises: FDA's January 2024 CAR T guidance says cytokine release and killing should be antigen-dependent, testable with cells that vary in target antigen expression, and asks sponsors to assess targeting of healthy tissue that expresses the intended antigen (on-target, off-tumour) and of other antigens (off-target); activity against antigen-positive healthy cells would therefore show target-dependent activity and a safety concern, not selective cancer killing. Where engineered cells act is a further question: a later study with targeted lipid nanoparticles reports reprogrammed CD8-positive T cells from healthy donors and autoimmune patients, tumour control in humanised mice and B-cell depletion in cynomolgus monkeys, each a different experiment and setting (Hunter and colleagues; abstract only). For a vaccine the address can instead be an antigen-presenting cell: intravenous RNA-lipoplexes were aimed at dendritic cells and macrophages in lymphoid compartments by adjusting net charge, without a molecular ligand (Kranz and colleagues).","asOf":"2026-11-09","links":[{"label":"CAR T cells produced in vivo to treat cardiac injury.","url":"https://doi.org/10.1126/science.abm0594"},{"label":"In vivo CAR T cell generation to treat cancer and autoimmune disease.","url":"https://doi.org/10.1126/science.ads8473"},{"label":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.","url":"https://doi.org/10.1038/nature18300"},{"label":"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products: guidance for industry, January 2024","url":"https://www.fda.gov/media/156896/download"}],"tags":[],"related":["in-vivo-car-t","binder-targeting-module","mrna-construct-anatomy"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Separate delivery-marker binding, uptake, expression, receptor engagement, signalling and target-cell effects. A comparison needs identified live-cell populations and matched antigen-positive and antigen-negative controls. A small amount of unintended-cell expression in a sample cannot establish absence across all cells or tissues, and selectively engineering one cell population does not remove risk to healthy antigen-positive targets."],"category":"Treatment jargon"},"route":"/terms/delivery-target-versus-therapeutic-target/","neighbours":{"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"term":[{"id":"binder-targeting-module","kind":"term","name":"Binders as targeting modules","route":"/terms/binder-targeting-module/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"mrna-construct-anatomy","kind":"term","name":"Messenger RNA construct anatomy","route":"/terms/mrna-construct-anatomy/"}]}}